ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

INTRON A SOLN
Kaposi's sarcoma
Leukemias, lymphomas, and other hematologic cancers
Melanoma and other skin cancers
Viral infections
Warts
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

INTRON A SOLN Rx

Generic Name and Formulations:
Interferon alfa-2b, recombinant; 10 million IU, 18 million IU, 25 million IU; per vial; for inj; contains m-cresol.

Company:
Merck & Co., Inc.

Therapeutic Use:

Indications for INTRON A SOLN:

AIDS-related Kaposi's sarcoma. Not for patients with rapidly progressive visceral disease.

Adult:

Use appropriate preparation and route: see full labeling. Use pwd form only. 30 million IU/m2 IM or SC three times weekly; continue until disease progression or maximal response achieved after 16 weeks; reduce dose by ½ or suspend therapy if severe adverse reactions occur; discontinue if persists.

Children:

18yrs: not established.

Contraindications:

Decompensated liver disease. Autoimmune hepatitis.

Warnings/Precautions:

May cause or exacerbate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, or infectious disorders: monitor closely, discontinue if they worsen. Cardiovascular disease (eg, MI, arrhythmias); monitor closely. Pulmonary disease (eg, COPD). Discontinue if severe psychiatric disorders (eg, suicidal behavior) or new/worsening ophthalmologic reactions develop. Severe myelosuppression; discontinue if neutrophil count <0.5 X109/L or platelets 25X109/L. Permanently discontinue if severe (Grade 3) hepatic injury or decompensation (Child-Pugh score >6 [Class B and C]) develop. Thyroid abnormalities; discontinue if uncontrolled by medication. Diabetes. Coagulation disorders. Maintain adequate hydration. Monitor CBCs, platelets, thyroid, visual and liver function before and during therapy; EKG in cardiovascular disease and cancer patients. Pwd: contains human albumin; monitor for possible viral disease and Creutzfeldt-Jakob disease transmission. Pre-existing psoriasis or sarcoidosis. Renal impairment. Transplant recipients. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:

Caution with myelosuppressive agents (eg, zidovudine), and drugs that can exacerbate depression. May potentiate theophylline. Increased risk of peripheral neuropathy with concomitant telbivudine. Dental/periodontal disorders, dry mouth with concomitant ribavirin.

See Also:

INTRON A

Pharmacological Class:

Alpha interferon.

Adverse Reactions:

Flu-like symptoms (fever, headache, chills, myalgia, fatigue); abnormal LFTs, blood, cardiovascular, pulmonary, thyroid, and GU disorders, GI upset, abnormal vision, skin reactions, CNS/psychiatric reactions, colitis, hypertriglyceridemia, pancreatitis; rare: autoimmune disorders, hypersensitivity. See full labeling.

How Supplied:

Pwd (w. diluent): 10million, 18million, 50million IU/vial—1; Soln (multidose vials): 18million, 25million IU/vial—1

Indications for INTRON A SOLN:

Hairy cell leukemia. Initial treatment of clinically aggressive follicular Non-Hodgkin's lymphoma in conjunction with anthracycline-containing combination chemotherapy.

Adult:

Use appropriate preparation and route: see full labeling. Use SC route if platelets <50,000/mm3. Hairy cell leukemia: 2 million IU/m2 IM or SC 3 times a week for up to 6 months. Follicular lymphoma: 5 million IU SC 3 times a week for up to 18 months in conjunction with anthracycline-containing chemotherapy regimen and following completion of the chemotherapy regimen. Dose adjustments for toxicity: see full labeling.

Children:

18yrs: not established.

Contraindications:

Decompensated liver disease. Autoimmune hepatitis.

Warnings/Precautions:

May cause or exacerbate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, or infectious disorders: monitor closely, discontinue if they worsen. Cardiovascular disease (eg, MI, arrhythmias); monitor closely. Pulmonary disease (eg, COPD). Discontinue if severe psychiatric disorders (eg, suicidal behavior) or new/worsening ophthalmologic reactions develop. Severe myelosuppression; discontinue if neutrophil count <0.5 X109/L or platelets 25X109/L. Permanently discontinue if severe (Grade 3) hepatic injury or decompensation (Child-Pugh score >6 [Class B and C]) develop. Thyroid abnormalities; discontinue if uncontrolled by medication. Diabetes. Coagulation disorders. Maintain adequate hydration. Monitor CBCs, platelets, thyroid, visual and liver function before and during therapy; EKG in cardiovascular disease and cancer patients. Pwd: contains human albumin; monitor for possible viral disease and Creutzfeldt-Jakob disease transmission. Pre-existing psoriasis or sarcoidosis. Renal impairment. Transplant recipients. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:

Caution with myelosuppressive agents (eg, zidovudine), and drugs that can exacerbate depression. May potentiate theophylline. Increased risk of peripheral neuropathy with concomitant telbivudine. Dental/periodontal disorders, dry mouth with concomitant ribavirin.

See Also:

INTRON A

Pharmacological Class:

Alpha interferon.

Adverse Reactions:

Flu-like symptoms (fever, headache, chills, myalgia, fatigue); abnormal LFTs, blood, cardiovascular, pulmonary, thyroid, and GU disorders, GI upset, abnormal vision, skin reactions, CNS/psychiatric reactions, colitis, hypertriglyceridemia, pancreatitis; rare: autoimmune disorders, hypersensitivity. See full labeling.

How Supplied:

Pwd (w. diluent): 10million, 18million, 50million IU/vial—1; Soln (multidose vials): 18million, 25million IU/vial—1

Indications for INTRON A SOLN:

Malignant melanoma, as adjuvant to surgical treatment in patients who are free of disease but at high risk for systemic recurrence, within 56 days of surgery.

Adult:

Use appropriate preparation and route: see full labeling. Induction: use pwd form only. 20million IU/m2 IV over 20mins, 5 consecutive days per week, for 4wks. Maintenance: 10 million IU/m2 SC 3 times per week for 48wks. Dose adjustments for toxicity: see full labeling.

Children:

18yrs: not established.

Contraindications:

Decompensated liver disease. Autoimmune hepatitis.

Warnings/Precautions:

May cause or exacerbate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, or infectious disorders: monitor closely, discontinue if they worsen. Cardiovascular disease (eg, MI, arrhythmias); monitor closely. Pulmonary disease (eg, COPD). Discontinue if severe psychiatric disorders (eg, suicidal behavior) or new/worsening ophthalmologic reactions develop. Severe myelosuppression; discontinue if neutrophil count <0.5 X109/L or platelets 25X109/L. Permanently discontinue if severe (Grade 3) hepatic injury or decompensation (Child-Pugh score >6 [Class B and C]) develop. Thyroid abnormalities; discontinue if uncontrolled by medication. Diabetes. Coagulation disorders. Maintain adequate hydration. Monitor CBCs, platelets, thyroid, visual and liver function before and during therapy; EKG in cardiovascular disease and cancer patients. Pwd: contains human albumin; monitor for possible viral disease and Creutzfeldt-Jakob disease transmission. Pre-existing psoriasis or sarcoidosis. Renal impairment. Transplant recipients. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:

Caution with myelosuppressive agents (eg, zidovudine), and drugs that can exacerbate depression. May potentiate theophylline. Increased risk of peripheral neuropathy with concomitant telbivudine. Dental/periodontal disorders, dry mouth with concomitant ribavirin.

See Also:

INTRON A

Pharmacological Class:

Alpha interferon.

Adverse Reactions:

Flu-like symptoms (fever, headache, chills, myalgia, fatigue); abnormal LFTs, blood, cardiovascular, pulmonary, thyroid, and GU disorders, GI upset, abnormal vision, skin reactions, CNS/psychiatric reactions, colitis, hypertriglyceridemia, pancreatitis; rare: autoimmune disorders, hypersensitivity. See full labeling.

How Supplied:

Pwd (w. diluent): 10million, 18million, 50million IU/vial—1; Soln (multidose vials): 18million, 25million IU/vial—1

Indications for INTRON A SOLN:

Chronic hepatitis C with compensated liver disease, with or without ribavirin. Chronic hepatitis B with compensated liver disease.

Adults and Children:

Use appropriate preparation and route: see full labeling. Hepatitis C: use soln form only. ≥18yrs: 3 million IU IM or SC three times weekly for 16 weeks; if tolerated with normalization of ALT, continue to 18–24 months (72–96 weeks). With concomitant ribavirin (in previously untreated patients [≥3yrs] or those who relapsed after alpha interferon [≥18yrs]): see full labeling. Hepatitis B: <1yr: not established. 1–17yrs: 3million IU/m2 SC three times weekly for 1 week, then increase to 6million IU/m2 (max 10 million IU) three times weekly for a total of 16–24 weeks. ≥18yrs: 5 million IU daily or 10million IU IM or SC three times weekly for 16 weeks. Dose adjustments for toxicity: see full labeling. HCV/HBV co-infection: not studied.

Contraindications:

Decompensated liver disease. Autoimmune hepatitis. When co-administered with ribavirin, its contraindication also apply to the combination regimen (eg, Pregnancy Cat.X).

Warnings/Precautions:

May cause or exacerbate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, or infectious disorders: monitor closely, discontinue if they worsen. Cardiovascular disease (eg, MI, arrhythmias); monitor closely. Pulmonary disease (eg, COPD). Discontinue if severe psychiatric disorders (eg, suicidal behavior) or new/worsening ophthalmologic reactions develop. Severe myelosuppression; discontinue if neutrophil count <0.5 X109/L or platelets 25X109/L. Permanently discontinue if severe (Grade 3) hepatic injury or decompensation (Child-Pugh score >6 [Class B and C]) develop. Thyroid abnormalities; discontinue if uncontrolled by medication. Diabetes. Coagulation disorders. Maintain adequate hydration. Monitor CBCs, platelets, thyroid, visual and liver function before and during therapy; EKG in cardiovascular disease and cancer patients. Pwd: contains human albumin; monitor for possible viral disease and Creutzfeldt-Jakob disease transmission. Pre-existing psoriasis or sarcoidosis. Renal impairment. Transplant recipients. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:

Caution with myelosuppressive agents (eg, zidovudine), and drugs that can exacerbate depression. May potentiate theophylline. Increased risk of peripheral neuropathy with concomitant telbivudine. Dental/periodontal disorders, dry mouth with concomitant ribavirin.

See Also:

INTRON A

Pharmacological Class:

Alpha interferon.

Adverse Reactions:

Flu-like symptoms (fever, headache, chills, myalgia, fatigue); abnormal LFTs, blood, cardiovascular, pulmonary, thyroid, and GU disorders, GI upset, abnormal vision, skin reactions, CNS/psychiatric reactions, colitis, hypertriglyceridemia, pancreatitis; rare: autoimmune disorders, hypersensitivity. See full labeling.

How Supplied:

Pwd (w. diluent): 10million, 18million, 50million IU/vial—1; Soln (multidose vials): 18million, 25million IU/vial—1

Indications for INTRON A SOLN:

Genital warts.

Adult:

Use appropriate preparation and route: see full labeling. Inject intralesionally 1 million IU/lesion 3 times weekly on alternate days for 3 weeks; max 5 lesions per treatment. May repeat treatment as above after 12–16 weeks.

Children:

18yrs: not established.

Contraindications:

Decompensated liver disease. Autoimmune hepatitis.

Warnings/Precautions:

May cause or exacerbate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, or infectious disorders: monitor closely, discontinue if they worsen. Cardiovascular disease (eg, MI, arrhythmias); monitor closely. Pulmonary disease (eg, COPD). Discontinue if severe psychiatric disorders (eg, suicidal behavior) or new/worsening ophthalmologic reactions develop. Severe myelosuppression; discontinue if neutrophil count <0.5 X109/L or platelets 25X109/L. Permanently discontinue if severe (Grade 3) hepatic injury or decompensation (Child-Pugh score >6 [Class B and C]) develop. Thyroid abnormalities; discontinue if uncontrolled by medication. Diabetes. Coagulation disorders. Maintain adequate hydration. Monitor CBCs, platelets, thyroid, visual and liver function before and during therapy; EKG in cardiovascular disease and cancer patients. Pwd: contains human albumin; monitor for possible viral disease and Creutzfeldt-Jakob disease transmission. Pre-existing psoriasis or sarcoidosis. Renal impairment. Transplant recipients. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:

Caution with myelosuppressive agents (eg, zidovudine), and drugs that can exacerbate depression. May potentiate theophylline. Increased risk of peripheral neuropathy with concomitant telbivudine. Dental/periodontal disorders, dry mouth with concomitant ribavirin.

See Also:

INTRON A

Pharmacological Class:

Alpha interferon.

Adverse Reactions:

Flu-like symptoms (fever, headache, chills, myalgia, fatigue); abnormal LFTs, blood, cardiovascular, pulmonary, thyroid, and GU disorders, GI upset, abnormal vision, skin reactions, CNS/psychiatric reactions, colitis, hypertriglyceridemia, pancreatitis; rare: autoimmune disorders, hypersensitivity. See full labeling.

How Supplied:

Pwd (w. diluent): 10million, 18million, 50million IU/vial—1; Soln (multidose vials): 18million, 25million IU/vial—1

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs